GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Source review / handoff

Bortezomib (Velcade), IV / subcutaneous injection

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

Velcade - labeled renal guidance

Product / population
Bortezomib (Velcade), IV / subcutaneous injection
Renal method
Renal impairment categories as defined by the cited product label
Source revision
DailyMed SPL version 36, posted Sep 01, 2025
Retrieved
2026-11-07
Local review status
Selected renal passages reviewed; independent clinician adjudication pending.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Velcade - product and source limitations

Use the regimen and administration route appropriate to the indication. Follow toxicity separately.

What to reconcile: Apply only to the stated formulation, indication and renal population.

Selected renal passages reviewed; independent clinician adjudication pending.

Open this note and its source references
Official

Velcade - labeled renal guidance

Open original reference

DailyMed / product prescribing information · Bortezomib (Velcade), IV / subcutaneous injection

Renal method: Renal impairment categories as defined by the cited product label
Source date: DailyMed SPL version 36, posted Sep 01, 2025
Retrieved: 2026-11-07

Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment

Bortezomib does not require an initial renal reduction. On dialysis days, administer it after the dialysis procedure. Use the regimen and administration route appropriate to the indication. Follow toxicity separately.

RDM74-velcade-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1521d321-e724-4ffc-adad-34bf4f44fac7
Retrieved
2026-11-07
Renal-function method
Renal impairment categories as defined by the cited product label
Source date/version
DailyMed SPL version 36, posted Sep 01, 2025
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
9b7760e92ef60eaf6d1448c574cf747ef11d712dbec6a243ecce834bec956a36

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rx-velcade&s1=RDM74-velcade-official&h1=bac5e05ffa9e129d5b21b0159e9f3821450d3aee8750456f465334f439cd9a81

Top